ArticleGlobal health, science and practice2021
Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study.
Article in Global health, science and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06316492 (Knowledge, Attitude, and Practice of Viral Hepatitis), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Knowledge, Attitude, and Practice of Viral Hepatitis ( B and C) Among Population in a Village in New Valley Governorate
Who cites it
38 citing papers in PubMed.
- Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model.Tropical medicine and infectious disease · 2026Article
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan.Journal of viral hepatitis · 2026Article
- Hepatocellular Carcinoma in Africa: Epidemiology, Prevention and Outcomes.Current hepatology reports · 2026Review
- Integrated Care Models for Hepatitis C: Lessons From Southeast Asia and Sub-Saharan Africa.Open forum infectious diseases · 2025Article
- Deep Sequencing Analysis of Hepatitis C Virus Subtypes and Resistance-Associated Substitutions in Genotype 4 Patients Resistant to Direct-Acting Antiviral (DAA) Treatment in Egypt.International journal of molecular sciences · 2025Article
- Review
- Hepatitis Management in Saudi Arabia: Trends, Prevention, and Key Interventions (2016-2025).Medicina (Kaunas, Lithuania) · 2025Review
- Assessing user experience with the Bioline™ HCV point-of-care test in primary healthcare settings: a mixed-methods study.BMC health services research · 2025Article
- Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.Journal of viral hepatitis · 2025Article
- Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis.BMJ public health · 2025Article
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C.Tropical medicine and infectious disease · 2024Article
- The Interplay Between Schistosomiasis and Hepatitis C Virus: Battling on Two Fronts.Infectious diseases & immunity · 2024Article
- Hepatitis C Elimination in Egypt: Story of Success.Pathogens (Basel, Switzerland) · 2024Review
- Assessment of hepatitis c core antigen in epithelial salivary gland neoplasms (ex-vivo study).BMC oral health · 2024Article
- Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study.The Lancet regional health. Western Pacific · 2024Article
- Towards eliminating hepatitis C as a public health threat: different speeds, different needs.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- Prevalence and risk factors of Hepatitis C virus infection in the Upper East Region of Ghana; a community-based cross-sectional study.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionChronic hepatitis C virus (HCV) infection is a major public health problem in many low- and middle-income countries. In 2015, Egypt's HCV infection prevalence of 7% among adults was among the highest in the world and accounted for 7.6% of the country's mortality. In 2014, Egypt embarked on an aggressive screening and treatment program that evolved into a national strategy to eliminate HCV as a public health threat by 2021.
methodsIn this qualitative case study, we analyzed Egypt's HCV control strategy using the Kingdon framework to understand how the problem, policy, and political streams merged to create an opportunity to achieve an ambitious elimination goal. We describe key aspects of the implementation, identify lessons learned, and provide recommendations for other low- and middle-income countries aiming to eliminate HCV.
resultsBetween 2014 and 2020, Egypt screened more than 50 million and treated more than 4 million residents for HCV. Five key elements contributed to Egypt's successful HCV elimination program: (1) sufficient and reliable epidemiologic data to quantify and monitor public health threats; (2) a robust public health care infrastructure; (3) inclusive care that reached all sectors of society; (4) increased health care spending; and (5) innovative scientific research and use of information technology.
conclusionEgypt conducted a successful HCV screening program that covered more than 50 million residents and treated more than 4 million. It is poised to be the first country in the world to eliminate HCV within its borders. The lessons learned from this experience can inform the elimination plans of other low- and middle-income countries with high HCV burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.